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Abstract
Background: Mycobacterium tuberculosis Uganda family is the predominant cause of tuberculosis in Uganda.
Reasons for this are not clear but are likely to be due to the rampant person-to-person transmission or delayed
susceptibility of the organism to drugs during treatment, which may lead to continuous shedding of infectious
bacilli, among others. The objective of this study was to determine in vitro, the susceptibility patterns of M.
tuberculosis Uganda family compared with Beijing and Delhi/CAS, other M. tuberculosis sub-lineages that also
circulate in Uganda but are not as prevalent. The comparisons were made after 10 days of exposure of the strains
to Rifampicin and Isoniazid, the most important first-line anti-tuberculosis drugs.
Methods: Minimum inhibitory concentrations (MICs) for three Isoniazid- and Rifampicin-susceptible M. tuberculosis
strains (Uganda II, Beijing and Delhi/CAS families) were determined by micro-dilution plate assay. Killing curves for
each strain were deduced from colony forming units after exposure to Isoniazid and Rifampicin on days 0, 2, 4, 6, 8,
and 10 under aerobic and oxygen-depleted conditions. Data were analyzed with GraphPad Prism 5 software.
Results: The MIC for Isoniazid was 0.05 μg/ml for M. tuberculosis Uganda II, and 0.03 μg/ml for M. tuberculosis
Beijing and Delhi/CAS. Rifampicin MIC was 1 μg/ml for M. tuberculosis Uganda II, and 0.12 μg/ml for Beijing and
Delhi/CAS. At low Rifampicin (0.03–2.5 μg/ml) and Isoniazid (0.12–5 μg/ml) concentrations under aerobic
conditions, there was no significant difference in susceptibility patterns between M. tuberculosis Uganda II and
Beijing or Delhi/CAS. However, at high Rifampicin (5 μg/ml) and Isoniazid (1.25 μg/ml) concentrations under
oxygen-depleted conditions, M. tuberculosis Uganda II was more susceptible to the drugs compared with Beijing or
Delhi/CAS families.
Conclusion: The predominance of M. tuberculosis Uganda II family as the main causative agent of tuberculosis in
Uganda is not attributed to its susceptibility behavior to Isoniazid and Rifampicin. Probably, its predominance is due
to differences in the immune defenses in the general population against the strains, given that Beijing and Delhi/
CAS families may have been introduced more recently. Further research beyond susceptibility to anti-tuberculosis
drugs is required to fully explore tuberculosis strain predominance in Uganda.
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Background
Human tuberculosis is an important disease worldwide
second only to HIV/AIDS as the greatest killer attributed
to a sole infectious agent. Tuberculosis (TB) is caused by a
group of closely related bacteria referred to as the
“Mycobacterium tuberculosis complex” (MTBC) compris-
ing Mycobacterium tuberculosis, Mycobacterium bovis,
Mycobacterium bovis BCG, Mycobacterium africanum,
Mycobacterium canettii, Mycobacterium caprae, Mycobac-
terium microtii and Mycobacterium pinnipedii [1, 2].
Although the MTBC are highly identical at DNA level,
molecular genotyping data has revealed that genetic diver-
sity in form of single nucleotide polymorphisms (SNPs),
insertions & deletions (InDels), etc., occurs among the
MTBC strains, and maybe responsible for phenotypic
differences in drug susceptibility, pathogenicity, host trop-
ism, transmissibility, immune response, and geographical
distribution of the strains [1, 3]. In light of this, the MTBC
are classified into seven lineages (Lineage 1 to 7) [1–3]
globally distributed with some lineage-types being more
predominant than others in certain geographical regions
and human populations [2, 3]. Lineage 4 (Euro-American)
is commonly found in Africa, America, and Europe while
Lineage 2 (East-Asia) is prevalent in Asia [3]; all the seven
human-adapted MTBC lineages do circulate in Africa
where MTBC appears to have originated, accompanying
human migrations over millennia [2].
M. tuberculosis Uganda is a sub-lineage of the M. tu-
berculosis lineage 4, the Euro- American lineage which is
defined by RD 724 deletion [4–8]. The M. tuberculosis
Uganda family comprises M. tuberculosis Uganda I and
Uganda II subfamilies with the latter being more preva-
lent in Uganda [5, 7]. Asiimwe et al., 2008 [4], Nabyonga
et al., 2011 [7], and more recently Ezati et al., 2014 [5],
reported higher occurrence in Uganda of the M. tuber-
culosis Uganda subfamily (>70 %) compared with other
genotypes combined (LAM, Delhi/CAS and Beijing fam-
ilies about 3 % each). However, little is known about the
mechanisms that are responsible for this predominance
in Uganda. Other than chance, one possibility is that
the transmission of M. tuberculosis Uganda family in
Ugandan populations is influenced by the level of drug
susceptibility compared to the less predominant strains.
Furthermore, M. tuberculosis has a long generation time
and capacity for dormancy, where its low metabolic activ-
ity complicates treatment options [9]. The bacilli can be
located in pulmonary cavities, empyema, pus, or solid ca-
seous material, where penetration by antibiotics is difficult
or the pH is sufficiently low to inhibit the activity of most
antibiotics [10]. Indeed, animal and human clinical trials
have led to the concept that there are different popula-
tions of bacteria present within the host [11, 12]. Organ-
isms in pulmonary cavities are thought to be multiplying
in an aerobic environment and consequently behave in a
way that can be mimicked by in vitro tests. Organisms lo-
cated within caseous foci are in a milieu where the low
pH is likely to inhibit the activity of agents such as amino-
glycosides but provide the conditions necessary for pyrazi-
namide activity [13]. Bacteria found within macrophages
probably exhibit occasional spurts of metabolism and
may be in relatively microaerophilic conditions, where
mycobacterial dormancy can be induced [13]. Organ-
isms located within granulomas are in a milieu where
the oxygen is depleted.
Most diagnostic susceptibility tests guiding TB treat-
ment investigate metabolically active bacilli under static
conditions and as such, they may not be informative
with respect to time-kill kinetics of anti-TB drugs and
the emergence of resistance in low metabolically active
or even dormant mycobacterial cells [14]. The kinetics
of antimicrobial activity is generally used to evaluate and
compare new drugs and study differences and changes
in the antimicrobial susceptibilities of clinically import-
ant bacterial isolates [15]. The time-killing-curve method
has been used in many studies, since bacterial death is
evaluated with more information by this method than by
end-point methods. As a means of data analysis, math-
ematical modeling is anticipated to be a useful tool in
describing and comparing kinetics, leading to quantita-
tive appraisal of bactericidal effects [16]. The pharmaco-
dynamics of TB treatment should be further explored, to
prevent emergence of resistance, treatment failure, re-
lapse of infection [14] and determine the drug response
of different genotypes.
In this study, we used time-kill-kinetics of Rifampicin
and Isoniazid, the most important first-line anti-TB drugs,
against selected strains under aerobic and oxygen-
depleted conditions, and determined the response of M.
tuberculosis Uganda family to drugs, and whether this re-
sponse might better explain its successful predominance
in Uganda.
Methods
Study site and setting
This was a laboratory-based study conducted at the Uganda
National Tuberculosis Reference Laboratory (NTRL) and
the Medical & Molecular Laboratory of the Department
of Medical Microbiology, College of Health Sciences,
Makerere University. The NTRL is a fully equipped Bio-
safety Level 3 Laboratory where TB culture is routinely
done. Molecular tests to confirm Mycobacterium isolates
to species level, as well as strain families, were performed
at the Medical & Molecular Laboratory.
Isolates and drug susceptibility testing
Mycobacterium tuberculosis isolates were obtained from
the Joint Clinical Research Centre (JCRC), Kampala.
Drug susceptibility testing was previously performed at
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the JCRC and the isolates were found to be susceptible
to both Isoniazid and Rifampicin. The isolates were pre-
viously confirmed to species level through Region of
Difference PCR analysis [4], and genotyped by MIRU-
VNTR to confirm they were M. tuberculosis Beijing,
Uganda II, and Delhi/CAS families [7, 17].
At NTRL, the retrieved isolates (Beijing, Uganda II and
CAS/Delhi) were sub-cultured by incubating at 37 °C for
21 days on Middlebrook 7H11 agar supplemented with
OADC. Bacterial suspensions used in subsequent assays
were prepared by resuspending single colonies of each
strain into 1 ml of sterile distilled water.
Drug susceptibility testing was repeated using pheno-
typic and genotypic approaches; Middlebrook 7H10 agar
proportion method and line probe assays (Genotype
MTBDRplus, Hain Life Sciences, Germany), respectively.
With both methods all the isolates were confirmed to be
fully susceptible to Isoniazid and Rifampicin.
Genotyping
Chromosomal DNA used as templates in PCRs was pre-
pared as previously described [17]. Similarly, the M. tuber-
culosis spoligotypes were determined by Spoligotyping as
recently described [6]. The isolates were re-genotyped
using MIRU-VNTR [17] and SNP-based Real-Time PCR
[8] to confirm that they belong to M. tuberculosis Beijing,
Uganda II and Delhi/CAS families.
Determination of minimum inhibitory concentrations
Isoniazid and Rifampicin were purchased from Sigma-
Aldrich (St. Louis, MO). Stock concentrations at 10 mg/ml
were prepared using either sterile distilled water (Ri-
fampicin) or Dimethyl Sulphoxide (DMSO) (Isoniazid).
To determine the minimum inhibitory concentrations
(MICs), microdilution plate assays were performed as
described by Wallace et al., 1986 [18] and Lenaerts et
al., 2005 [19]. Bacterial suspensions were adjusted to
McFarland standard of 0.5, 100 μl of which were inocu-
lated into 11 ml Middlebrook 7H9 medium supplemented
with glycerol and OADC, to give a desired inoculum
of 1 x 105 colony forming units (CFU) per ml.
Microtitre plate wells were seeded with 98 μl of the
bacterial suspension, into which 2 μl of drug was added.
The final concentration of drugs ranged from 0.03–
4.0 μg/ml (Isoniazid) and 0.12-16 μg/ml (Rifampicin).
Control wells contained only DMSO or water. The outer
wells of the plates were filled with water to avoid evapor-
ation from the sample wells. The plates were sealed with
perforated parafilm and incubated at 37 °C for 21 days.
Plates were observed weekly to monitor changes in
growth. Growth inhibition was determined by visual
examination. The MIC was determined as the lowest
drug concentration with no visible bacterial growth after
3 weeks of incubation. Duplicate MICs per strain were
determined. In all assays the M. tuberculosis reference
strain, H37Rv, was used as the control.
Determination of killing curves under aerobic conditions
The MICs above were used to calculate the final drug
concentration per strain that was used in determining
killing curves. The bacterial suspensions were adjusted
to an inoculum of Log10 7.0 CFU/ml (range of Log10
6.9–8.2 CFU/ml), as described above. To the bacterial
suspension, drugs were added to final concentrations
of; 1x MIC, 2x MIC and 5x MIC, and incubated at
37 °C. As such, the concentrations for Isoniazid were:
0.5 μg/ml (1x MIC), 1 μg/ml (2x MIC) and 2.5 μg/ml
(5x MIC) for Uganda II; 0.03 μg/ml (1x MIC),
0.06 μg/ml (2x MIC) and 0.15 μg/ml (5x MIC) for
both Beijing and Delhi/CAS. Further, the concentra-
tions for Rifampicin were: 1 μg/ml (1x MIC), 2 μg/ml
(2x MIC) and 5 μg/ml (5x MIC) for Uganda II;
0.12 μg/ml (1x MIC), 0.24 μg/ml (2x MIC) and
0.6 μg/ml (5x MIC) for both Beijing and Delhi/CAS.
The day on which the drug was added to the cultures
was defined as day 0 and the corresponding CFUs were
taken as 100 %. On days 0, 2, 4, 6, 8 and 10, one milli-
liter was drawn from each tube and serially diluted with
sterile distilled water. One hundred microliters of the di-
luted culture was plated onto Middlebrook 7H11 agar
supplemented with OADC, and incubated at 37 °C
under normal atmospheric conditions. After 21 days,
CFUs/ml were determined and were used to calculate
the log10 CFUs/ml.
Determination of killing curves under oxygen depleted
conditions
We employed Wayne’s model as described by Murugasu-
Oei et al., 2000 [20] with a few modifications to suit our
setting. Bacterial suspensions were prepared as explained
above. Tubes were closed with sterile silicone rubber
septa, and incubated at 37 °C with slow stirring for 24 days.
Control tubes, in addition to the culture, contained the
Methylene Blue dye (1.5 g/ml), which was used as an indi-
cator of oxygen depletion. The blue dye faded and disap-
peared indicating that oxygen is successfully depleted in
the culture, as described by Wayne and Hayes, 1996 [21].
The drugs were injected into cultures through the septa
on day 24 at concentrations based on MICs. Controls had
no drug but water or DMSO. The cultures were incubated
at 37 °C for 10 days.
On days 0, 2, 4, 6, 8 and 10, one milliliter from each
tube was serially diluted in sterile distilled water, and
100 μl of the diluted culture incubated at 37 °C on Mid-
dlebrook 7H11 agar plates supplemented with OADC
under normal atmospheric conditions. Colonies were
counted after 21 days.
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Data analysis
To test the hypothesis that there is a difference in re-
sponse to anti-TB drugs between M. tuberculosis Uganda
and other families, data were analyzed with the Student’s
t-distribution test to compare responses of M. tubercu-
losis Uganda II vs. Beijing, and Uganda II vs. Delhi/CAS.
The means of the different killing curves were compared
and a p-value of <0.05 at 95 % CI and α = 0.05 was
considered significant. The data was analyzed with
GraphPad Prism statistical program version 5.
Definitions
In this study, strain refers to any of the seven MTBC line-
ages [3] or sub-lineages; hence, strain = lineage/sub-lineage.
Results
Minimum inhibitory concentrations
The MIC for Isoniazid was 0.05 μg/ml for M. tuberculosis
Uganda II, and 0.03 μg/ml for both Beijing and Delhi/CAS
families. Rifampicin MIC was 1 μg/ml for M. tuberculosis
Uganda II, and 0.12 μg/ml for both Beijing and Delhi/
CAS. Thus, compared with the other two strains, M.
tuberculosis Uganda II required higher Isoniazid and
Rifampicin concentrations to inhibit its growth.
Isoniazid is more effective under aerobic conditions than
oxygen-depleted conditions
Under aerobic and oxygen depleted conditions, the
CFU/ml of control cultures (no Isoniazid added) in-
creased from days 0 to 10, Fig. 1. For instance, on day 0
the Log10 CFU/ml for M. tuberculosis Uganda II control
was 7.8; it increased to 9.4 and 10.2 on days 4 and 10,
respectively. On adding Isoniazid to cultures, CFUs/ml
reduced both at low and high concentrations under aer-
obic conditions, Fig. 1. However, on adding Isoniazid
under oxygen depleted conditions, CFUs/ml did not
markedly reduce, Fig. 1. Hence, Isoniazid effectively
killed more under aerobic conditions than under
oxygen-depleted conditions. Table 1 shows the mean
bacterial counts (Log10 CFU/ml) after 10 day exposure
to Isoniazid and Rifampicin.
Furthermore, under aerobic conditions comparison of
the mean Log10 MICs of the pairs of killing curves for
M. tuberculosis Uganda II vs. Beijing; M. tuberculosis
Uganda II vs. Delhi/CAS was not statistically significant
at all Isoniazid concentrations tested (p-value >0.05),
Table 2. Likewise, under oxygen depleted conditions at
low Isoniazid concentrations (1x MIC, 2x MIC), the differ-
ences in mean Log10 MICs of the pairs of killing curves
for M. tuberculosis Uganda II vs. Beijing; M. tuberculosis
Uganda II vs. Delhi/CAS was not statistically significant
(p-value >0.05), Table 2. The exception was 5x MIC
Isoniazid under oxygen depleted conditions, where we
found the difference in mean Log10 MICs between M.
tuberculosis Uganda II vs. Beijing to be statistically signifi-
cant (p-value = 0.02, 95 % CI 0.019–0.169), Table 2.
Rifampicin is more effective than Isoniazid at killing M.
tuberculosis under oxygen-depleted conditions
Similar to Isoniazid, the CFU/ml of controls where no
Rifampicin was added, increased from days 0 to 10 both
under aerobic and oxygen depleted conditions, Fig. 2.
However, in contrast to Isoniazid, Rifampicin reduced the
CFUs beyond day 0 under both aerobic and oxygen
depleted conditions, Fig. 2. This result was more pro-
nounced at high Rifampicin concentrations (2x MIC, 5x
MIC) under oxygen depleted conditions, Fig. 2. Overall,
both drugs were more effective at killing the bacilli under
aerobic conditions compared to oxygen depleted condi-
tions, although this difference was more pronounced for
Fig. 1 The effect of Isoniazid on M. tuberculosis Uganda II, Beijing and Delhi/CAS. Panel A1, aerobic conditions. control b, Beijing with no drug; control
c, Delhi/CAS with no drug; control u, Uganda II with no drug; ce0.03 μg/ml, Delhi/CAS at 1x MIC; ue0.5 μg/ml, Uganda II at 1x MIC; be0.03 μg/ml,
Beijing at 1x MIC; ce0.06 μg/ml, Delhi/CAS at 2x MIC; ue1 μg/ml, Uganda II at 2x MIC; be0.06 μg/ml, Beijing at 2x MIC; ce0.15 μg/ml, Delhi/CAS at 5x
MIC; ue2.5 μg/ml, Uganda II at 5x MIC; be0.06 μg/ml, Beijing at 5x MIC. Panel A2, same as in Panel A1 but under oxygen-depleted conditions
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Isoniazid. Thus, compared to Isoniazid, Rifampicin had
more killing ability of M. tuberculosis irrespective of strain
or genotype under oxygen depleted conditions.
Similarly for Rifampicin at low concentrations under
aerobic conditions, analysis of the pairs of the killing
curves for M. tuberculosis Uganda II vs. Beijing; M. tu-
berculosis Uganda II vs. Delhi/CAS did not show signifi-
cant difference in the means (p-value >0.05), Table 2.
Also, under oxygen depleted conditions at 1x MIC Ri-
fampicin concentration there was no significant differ-
ence in the killing curves (p-value >0.05). However, in
contrast to Isoniazid, Rifampicin showed more pairs
under oxygen depleted conditions, with significant
differences in mean MICs even at 2x MIC; M. tubercu-
losis Uganda II vs. Delhi/CAS (p-value = 0.01, 95 % CI
0.009–0.063 at 2x MIC; p-value = 0.005, 95 % CI
0.997–3.463 at 5x MIC); M. tuberculosis Uganda II vs.
Beijing (p-value = 0.004, 95 % CI −3.277–0.966) at 5x
MIC, Table 2.
Taken together, these data show that M. tuberculosis
Uganda II is more susceptible to Isoniazid and Rifampicin
than Beijing or Delhi/CAS families, particularly at high
drug concentrations under oxygen depletion.
Discussion
We have investigated drug-resistance and virulence as
factors associated with the predominance of the M. tu-
berculosis Uganda family in Uganda. In one of the stud-
ies, we found that the M. tuberculosis Uganda family is
three times less likely to be resistant to first-line anti-TB
drugs and five times less likely to be multidrug resistant,
compared to the non-Uganda II families [5]. Further-
more, in the other study investigating virulence we
found that the M. tuberculosis Uganda family was less
virulent as defined by cavitary disease [8]. Although re-
sponse to first-line anti-TB drugs would offer a better
explanation to predominance, in this study, we have
found no significant differences in the susceptibility pat-
terns between M. tuberculosis Uganda II vs. Beijing or
Delhi/CAS families, except at high drug concentrations
under oxygen-depleted conditions where the Uganda II
family was instead more susceptible to Rifampicin and
Isoniazid than the Beijing or Delhi/CAS families. There-
fore, in line with recent studies [4–6], the predominance
of M. tuberculosis Uganda family in Uganda may not be
attributed to its susceptibility behavior once exposed to
Isoniazid and Rifampicin.




Aerobic Oxygen depleted Aerobic Oxygen depleted
1x MIC 2x MIC 5x MIC 1x MIC 2x MIC 5x MIC 1x MIC 2x MIC 5x MIC 1x MIC 2x MIC 5x MIC
Uganda II 5.29 4.06 3.12 7.51 7.56 7.22* 5.45 4.11 2.86 5.03 3.91* 3.03*
Delhi/CAS 6.10 4.47 3.23 7.64 7.67 7.49 5.27 2.96 2.96 7.43 6.58* 5.23*
Beijing 5.48 4.10 3.30 7.64 7.51 7.36* 5.44 2.93 2.93 7.39 6.53 5.14*
*Where P-value was <0.05 when compared to Uganda II
Table 2 Analysis of pairs of killing curves for M. tuberculosis Uganda II vs. Beijing, and M. tuberculosis Uganda II vs. Delhi/CAS
1x MIC (Ug-0.5 μg/ml, Be-0.03
μg/ml, Ce-0.03 μg/ml)
2x MIC (Ug-1 μg/ml, Be-0.06
μg/ml, Ce-0.24 μg/ml)
5x MIC (Ug-0.25 μg/ml, Be-0.15
μg/ml, Ce-0.15 μg/ml)
Drug (condition) Strain p-value, mean of diffs (95 % CI) p-value, mean of diffs (95 % CI) p-value, mean of diffs (95 % CI)
INH (aerobic) Ug vs Be 0.30, −0.191 (−0.623–0.241) 0.40, −0.034 (−0.133–0.635) 0.33, −0.176 (−0.602–0.250)
Ug vs Ce 0.09, 0.809 (−0.187–1.806) 0.14, 0.408 (−0.199–1.016) 0.30, 0.103 (− 0.128–0.334)
INH (O2 depletion) Ug vs Be 0.13, −0.023 (−0.057–0.010) 0.17, 0.053 (−0.032–0.138) 0.02, 0.094 (0.019–0.169)*
Ug vs Ce 0.20, 0.025 (−0.018–0.069) 0.14, 0.408 (−0.199–1.016) 0.55, 0.027 (−0.083–0.137)
1x MIC (Ug-1 μg/ml, Be-0.121
μg/ml, Ce-0.12 μg/ml)
2x MIC (Ug-2 μg/ml, Be-0.24
μg/ml, Ce-0.24 μg/ml)
5x MIC (Ug-5 μg/ml, Be-0.6
μg/ml, Ce-0.6 μg/ml)
RIF (aerobic) Ug vs Be 0.93, 0.006 (−0.162–0.174) 0.12, −0.427 (1.025–0.169) 0.60, −0.603 (−0.603–0.391)
Ug vs Ce 0.34, −0.176 (−0.617–0.263) 0.07, 0.485 (−0.081–1.052) 0.49, 0.140 (−0.348–0.629)
RIF (O2 depletion) Ug vs Be 0.51, −0.040 (−0.187–0.107) 0.36, 0.011 (−0.018–0.041) 0.004, −2.137 (−3.277–0.996)*
Ug vs Ce 0.13, 0.073 (−0.033–0.179) 0.01, 0.036 (0.009–0.063)* 0.005, 2.230 (0.997–3.463)*
MIC, minimum inhibitory concentration; Ug, Uganda II; Ce, Delhi/CAS; Be, Beijing
INH, Isoniazid; RIF, Rifampicin;
*P-value <0.05
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The MICs for Rifampicin and Isoniazid showed that
the strains were fully susceptible to both drugs and the
killing curve phenomenon could be demonstrated. The
MICs for Isoniazid were in agreement with previous re-
ports [22] of 0.02–0.05 mg/ml and were equally effective
against all the three MTBC strains. Also, the MICs for
Rifampicin were in agreement with the previous study
[23] that reported 0.25–0.5 mg/L and 1 mg/L using agar
proportion method and micro-dilution resazurin assay,
respectively, for M. tuberculosis laboratory strain H37Rv
commonly used as the reference for in vitro studies, and
0.0625–0.125 mg/L for susceptible clinical isolates.
Generally under oxygen-depleted conditions, the less
predominant strains (M. tuberculosis Beijing and Delhi/
CAS families) were less susceptible at the highest test
concentrations of Isoniazid and Rifampicin (1.25 μg/ml
and 5 μg/ml, respectively). These strains had lower MICs
than M. tuberculosis Uganda II and probably respond
better in vivo where drug concentrations are higher than
the ones studied. Nevertheless, our test concentrations
are still lower than the peak concentrations of both
drugs in serum (3–7 μg/mL and 6–9 μg/mL for isoniazid
and rifampicin, respectively) [24], implying that different
responses may occur in vivo.
Although Isoniazid showed high and rapid activity
against replicating mycobacteria under aerobic condi-
tions, compared to Rifampicin, it exhibited poor activity
against them under conditions of low oxygen tension.
Increasing the drug concentrations did not change this
observation. This could be attributed to the fact that
Isoniazid targets Mycobacterium’s cell wall synthesis [19]
and is therefore more effective against actively replicat-
ing bacteria. The rapid activity of Isoniazid is further
supported by similar findings of de Steenwinkel et al.,
2010, where it also showed extremely rapid and
concentration-dependent killing while Rifampicin had
relatively slow and strongly time-dependent killing [14].
Furthermore, at low drug concentrations we noted no
significant difference in the way the three strains
responded to Isoniazid and Rifampicin under aerobic
conditions. This agrees with findings by Lenaert et al.,
2005, where Isoniazid showed little activity against the
non-replicating bacteria even when 2 μg/ml, 10 μg/ml,
and 50 μg/ml concentrations were used [19]. On the other
hand, Rifampicin showed a better activity than Isoniazid
at all concentrations tested under conditions of low oxy-
gen tension. This is supported by Lenaert et al., 2005 find-
ings, where 2 μg/ml, 10 μg/ml and 50 μg/ml of Rifampicin
was very effective against non-replicating M. tuberculosis
grown under conditions of oxygen depletion [19]. This is
because Rifampicin targets protein synthesis and is there-
fore active against non-replicating bacteria or low metab-
olizing bacteria [19] where it inhibits RNA synthesis by
inhibiting DNA-dependent RNA polymerase [25].
The inactive state of the tubercle bacilli was achieved
as described by Wayne and Hayes, 1996, resulting in a
state known as non-replicating phase 2 (NRP-2) of low
metabolic rate that is experienced during the conditions
of low oxygen tension [21]. However, apart from using
Methylene Blue dye to indicate that the low oxygen level
condition is achieved, we could not accurately measure
the level of oxygen tension [21].
In Uganda, latent and active TB are treated with simi-
lar drug regimen irrespective of the strain causing dis-
ease in the host. Given our findings, one can infer that
there is no need of genotyping the infecting strain of a
Fig. 2 The effect of Rifampicin on M. tuberculosis Uganda II, Beijing and Delhi/CAS. Panel B1, aerobic conditions. control b, Beijing with no drug;
control c, Delhi/CAS with no drug; control u, Uganda II with no drug; ce0.12 μg/ml, Delhi/CAS at 1x MIC; ue1 μg/ml, Uganda II at 1x MIC;
be0.12 μg/ml, Beijing at 1x MIC; ce0.24 μg/ml, Delhi/CAS at 2x MIC; ue2 μg/ml, Uganda II at 2x MIC; be0.24 μg/ml, Beijing at 2x MIC; ce0.6 μg/ml,
Delhi/CAS at 5x MIC; ue5 μg/ml, Uganda II at 5x MIC; be0.6 μg/ml, Beijing at 5x MIC. Panel B2, same as in Panel B1 but under
oxygen-depleted conditions
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patient before starting treatment or when judging
prophylaxis, since there is no significant difference in
killing. However, further research into this is required to
enable detailed comparisons; testing more strains at
wider range of drug concentrations that put into consid-
eration the serum levels achieved during treatment is
recommended.
Conclusions
At low Rifampicin and Isoniazid concentrations under
aerobic conditions, there is no difference in susceptibility
patterns between M. tuberculosis Uganda II and Beijing
or Delhi/CAS families. At high concentrations of the
same drugs under oxygen-depleted conditions, M. tuber-
culosis Uganda II is more susceptible to Rifampicin and
Isoniazid compared to Beijing or Delhi/CAS families.
Therefore, the predominance of the M. tuberculosis
Uganda II family as the main causative agent of TB in
Uganda cannot be attributed to its susceptibility behav-
ior as judged from the three selected strains. Probably,
its predominance is due to differences in the immune
defenses in the general population against the strains,
given that the M. tuberculosis Beijing and Delhi/CAS
families are likely to have been introduced more re-
cently. Further research beyond susceptibility to anti-TB
drugs is required to ascertain these.
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